Phosphatidylserine
Brain-cell phospholipid with modest, FDA-qualified support for age-related memory.
What is Phosphatidylserine?
Phosphatidylserine is a nootropic used for may produce small improvements in memory and learning in older adults with age-associated memory complaints or mild cognitive impairment.. NutriDex grades the human evidence as Moderate. Phosphatidylserine is a phospholipid concentrated in neuronal cell membranes and marketed as a memory-support nootropic. A 2022 systematic review and meta-analysis (9 studies, 961 participants, 100–300 mg/day for 6 weeks to 6 months) concluded it has a positive effect on memory in older adults with cognitive decline, and a 2024 RCT in older adults with mild cognitive impairment found small improvements in short-term memory, reasoning, and arithmetic over placebo. However, effect sizes are generally small and independent reviewers (e.g., the Alzheimer's Drug Discovery Foundation) note the changes are often not large enough to be clearly clinically relevant, with most trials being short and using differing PS sources that complicate comparison. The U.S. FDA granted only a 'qualified' health claim, explicitly stating that the supporting evidence is very limited and preliminary and that there is little scientific agreement that PS reduces dementia risk. Modern products are derived from soy or sunflower rather than the bovine-brain PS used in early studies. Overall the evidence is best characterized as moderate but modest: a plausible, well-tolerated option for age-related memory, not a proven treatment for dementia.
Purported Benefits
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Memory in older adults with cognitive decline/MCIMeta-analysis and several RCTs show positive memory effects, but effect sizes small and not clearly clinically meaningful. | Moderate | ↑ benefit · small | 4 |
| Dementia risk reductionFDA granted only a qualified claim, stating evidence is very limited/preliminary with little scientific agreement. | Preliminary | ↔ mixed | 1 |
| Working memory in healthy/middle-aged adultsTwo RCTs (often combination formulas) show small working-memory gains; confounded by co-ingredients (DHA, coffee cherry). | Preliminary | ↑ benefit · small | 2 |
| Exercise/stress cortisol bluntingSmall RCTs (n=10-75) show blunted exercise/stress cortisol at high doses; very small samples, mostly surrogate endpoints. | Preliminary | ↑ benefit · moderate | 3 |